Search research articles
Contact Us
Filters
Showing results (271-280 of 347) with videos related to
Page
of 35
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 3, 2020
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi, Shucai Zhang, Xingsheng Hu, et al.
The Lancet. Respiratory Medicine
|
June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Yuankai Shi, Lin Wu, Yinghua Ji, et al.
Frontiers in Oncology
|
August 27, 2019
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma
Xiaohong Han, Qiaoyun Tan, Sheng Yang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
August 25, 2010
[The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced Non-small-cell Lung Cancer.]
Xinyong Zhang, Liyan Xu, Hui Wang, et al.
Thoracic Cancer
|
August 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
Huiyang Shi, Miaohan Wang, Junling Li, et al.
Cancer Immunology, Immunotherapy : CII
|
June 8, 2023
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)
Yuankai Shi, Jie Cui, Hui Zhou, et al.
Plos One
|
November 25, 2015
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
Yuankai Shi, Junling Li, Shucai Zhang, et al.
BMC Cancer
|
April 11, 2023
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
Xingsheng Hu, Xinge Cui, Ziping Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Ligang Xing, Yueyin Pan, Yuankai Shi, et al.
Endocrine-Related Cancer
|
September 16, 2015
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
Francis Worden, Martin Fassnacht, Yuankai Shi, et al.
Page
of 35
Search research articles
Search
Showing results (271-280 of 347) with videos related to
Sort By:
Page
of 35
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 3, 2020
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi, Shucai Zhang, Xingsheng Hu, et al.
The Lancet. Respiratory Medicine
|
June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Yuankai Shi, Lin Wu, Yinghua Ji, et al.
Frontiers in Oncology
|
August 27, 2019
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma
Xiaohong Han, Qiaoyun Tan, Sheng Yang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
August 25, 2010
[The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced Non-small-cell Lung Cancer.]
Xinyong Zhang, Liyan Xu, Hui Wang, et al.
Thoracic Cancer
|
August 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
Huiyang Shi, Miaohan Wang, Junling Li, et al.
Cancer Immunology, Immunotherapy : CII
|
June 8, 2023
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)
Yuankai Shi, Jie Cui, Hui Zhou, et al.
Plos One
|
November 25, 2015
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
Yuankai Shi, Junling Li, Shucai Zhang, et al.
BMC Cancer
|
April 11, 2023
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
Xingsheng Hu, Xinge Cui, Ziping Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Ligang Xing, Yueyin Pan, Yuankai Shi, et al.
Endocrine-Related Cancer
|
September 16, 2015
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
Francis Worden, Martin Fassnacht, Yuankai Shi, et al.
Page
of 35